BSBabak Salimi

Babak Salimi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Babak Salimi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Maryam Mabani

    Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Sharareh Seifi

    Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Adnan Khosravi

    Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Science, Tehran, Iran

    1 shared publication
  • Adnan Khosravi

    Research Center of Thoracic Oncology (RCTO), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication
  • Ali Dehghanifard

    Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

    1 shared publication
  • Babak Daneshfard

    Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication

Latest Publications

  • Open Access

    Histopathological Patterns of Lung Cancer in Iran: A Single-Center Study

    by Babak Salimi, Sharareh Seifi, Adnan Khosravi, Sara Shiari, Raana Moradi, Babak Daneshfard, Maryam Mabani

    Background: Lung cancer (LC) is one of the leading causes of cancer-related deaths worldwide. In Iran, it is the second most common cause of cancer-related deaths for men and the third most common for women. This study aimed to examine the clinicopathological characteristics of Iranian patients with LC. Methods: Clinicopathological data of 1382 patients with primary LC diagnosed over 11 years (2012‒2023) at the "National Institute of Tuberculosis and Lung Disease" (NRITLD), Tehran, Iran, were retrospectively reviewed. Results: Adenocarcinoma was the most common type of cancer found in the patients (42.44%). The median age was 59.69 years (mean: 60.41 years) ranging 24–88 years. The mean male-to-female ratio was 3.65. Additionally, 65.84% of patients were smokers. The majority of patients (82.69 %) were diagnosed at an advanced stage (stage IV) of cancer. Conclusion: Although some of our findings are consistent with those of previous LC studies, there are some discrepancies, especially concerning the smoking status and median age of the Iranian patients. Therefore, additional clinical and epidemiological studies are needed to determine the impact of non-smoking factors, such as environmental exposure and genetic predisposition, on the development of LC.

  • Open Access

    Assessing the Sensitivity of Nested PCR Followed by Direct Sequencing on Exosomal DNA for EGFR Mutation Detection in NSCLC

    by Mohammad Mehdi Jahani, Parisa Mashayekhi, Mir Davood Omrani, Adnan Khosravi, Ali Dehghanifard, Sanam Azad Manjiri, Mahyar Zahraie, Maryam Mabani, Sharareh Seifi, Babak Salimi, et al.

    Background: Early and minimally invasive detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients is a promising tool to select patients for targeted therapy in order to improve their prognosis. This study aimed to identify a sensitive, cost-effective, and easily accessible noninvasive method for detecting the ...


  • COMPARISON OF IMMORTALIZATION ASSAY AND POLYMERASE CHAIN REACTION DETECTION OF EPSTEIN-BARR VIRUS IN PEDIATRIC TRANSPLANT RECIPIENTS AND CONTROL SAMPLES

    by Babak Salimi, Estella M. Alonso, Richard A. Cohn, Susan R. Mendley, Ben Z. Katz

    The polymerase chain reaction technique (PCR) has become a standard for the detection of Epstein-Barr virus ( EBV). Several studies have shown that solid organ transplant recipients fated to develop post-transplant lymphoproliferative disease (PTLD) have higher mean levels of EB viremia as measured by PCR. We directly compared PCR and immortalization assay (IA) for EBV detection from control cell lines as well as from peripheral blood monouclear cells (PBMC) and saliva samples from 9 pediatric solid organ transplant recipients. Results were expressed as the lowest amount of DNA and/or number of cells detected. All samples negative for EBV by PCR had amplifiable DNA detected using beta-actin primers. When control cell lines were assayed and positive in both assays, PCR was at least 200 times more sensitive than IA, as expected. When PBMC and saliva were compared, 1 patient, with a mononucleosis-like syndrome, was positive for EBV by IA only. When both IA and PCR were positive however, PCR was able to detect 5-500 times less EBV than IA, as expected. The associations of positive test with each assay and the diagnosis of PTLD were similar.